Biogen Will Construct $200 Million Gene Therapy Manufacturing Facility in North Carolina

Rare Daily Staff

Biogen said it plans to build a new $200 million gene therapy manufacturing facility at its Research Triangle Park manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple therapeutic areas.

Biogen is pursuing multiple modalities to treat serious neurological and neurodegenerative diseases. The new facility is designed to be a scalable gene therapy manufacturing center.

“We plan to build differentiated, sustainable, and advanced manufacturing capabilities to support our gene therapy programs and collaborations,” said Nicole Murphy, senior vice president of Global Manufacturing and Technical Operations. “This additional investment underscores our commitment to [Research Triangle Park] and our mission to deliver a reliable supply of high-quality medicines to the patients we serve.”

Through the new facility, Biogen aims to continue its investment in North Carolina and expand its existing operations and combined workforce of approximately 1,900 employees at both campuses in Research Triangle Park. Biogen anticipates that the new facility will create approximately 90 new jobs.

The site will encompass 175,000 square feet and is designed in compliance with the most advanced sustainability standards regarding energy use, waste management and water consumption.